We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Entresto

News List

Novartis says Entresto outperforms heart failure drug enalapril in key study firstwordpharma
November 13, 2018
Novartis presented study data at the American Heart Association's (AHA) scientific sessions showing that Entresto (sacubitril/valsartan) outperformed enalapril in patients with heart failure with reduced ejection fraction requiring hospitalisation for an
Here’s the Chance?! A Core Patent of Novartis’ Entresto in China is Fully Declared Invalid Caicai
January 18, 2018
The festive atmosphere has become increasingly strong as the Chinese New Year is approaching, and there has been good news in the pharmaceutical circle in China...
Which is to dominate the future heart failure drug market?(2) en-cphi.cn
October 27, 2017
Sales of Entresto® rising steadily upon the Class I recommendation by the European and American heart failure guideline...
Novartis heart-failure med Entresto cuts A1c biospectrumasia
March 21, 2017
Entresto is indicated to reduce the risk of cardiovascular (CV) death and hospitalization for HF in patients with chronic HF (NYHA Class II-IV) and reduced ejection fraction

Previous page 1 2 Next page